Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + fruquintinib + tegafur as third-line therapy in MSS metastatic colorectal cancer
ChiCTR2300079188Phase 2Recruiting
- Sponsor
- Three department of internal medicine, College of traditional Chinese medicine, Guangdong, China
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, fruquintinib and tegafur in colorectal cancer (CRC), sponsored by Three department of internal medicine, College of traditional Chinese medicine, Guangdong, China. Primary endpoints: Progression-free survival and Incidence rate of adverse drug events. Started Dec 2023; status: recruiting.
02
Drugs
sintilimabfruquintinibtegafur
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300079188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079188.